*April 2025*
The ongoing COCOON study of a prophylactic dermatologic regimen in reducing the incidence of skin- and nail-adverse reactions in patients treated with amivantamab plus lazertinib demonstrated “early success” in meeting its phase II primary endpoint, according to a March 27 presentation during the European Lung Cancer Congress (ELCC).
The one-to-one randomized study included 102 patients with EGFR-positive non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib for first-line therapy. Enrollees followed standard dermatologic management, which included sun protective clothing and the application of sunscreen of SPF 30 or greater and the avoidance of alcohol-based topical agents with reactive topical corticosteroids and systemic antibiotics. The study arm also assessed the prophylactic measures of:
- Doxycycline or minocycline 100 mg twice daily during weeks 1-12
- Clindamycin topical lotion daily to the scalp during weeks 13-52
- Chlorhexidine 4% topical solution to fingernails and toenails daily for 12 months
- La Roche-Posay Lipikar AP+M moisturizer daily for 12 months
